Leqembi Approved for Alzheimer’s Treatment in Australia
Australia’s Therapeutic Goods Administration has approved Leqembi (lecanemab) for adults with early Alzheimer’s disease who are APOE ε4 non-carriers...
No videos found.
Roche Presents New Ocrevus, Fenebrutinib Data at ECTRIMS
Roche used ECTRIMS 2025 to consolidate its multiple sclerosis franchise on two fronts: durability and diversification. New data show...
Synendos’ Positive Phase 1 Results Pave Way for Phase 2
Synendos Therapeutics has reported positive topline results from a completed Phase 1 program of SYT-510, a first-in-class selective endocannabinoid...
Biogen Announces Regulatory Update on High-Dose Nusinersen
Biogen has received a Complete Response Letter from the FDA for its supplemental filing to add a high‑dose regimen...
API & Mitacs Launch Pioneering Life Sciences Placement Program
Applied Pharmaceutical Innovation has launched the Life Sciences Placement Program in partnership with Mitacs, aiming to support 1,000 paid...
Synendos’ Phase 1 Breakthrough in Mental Health Treatment
Synendos Therapeutics reported positive topline Phase 1 results for SYT-510, a first-in-class Selective Endocannabinoid Reuptake Inhibitor, in healthy volunteers....
Veru’s Obesity Drug Breakthrough After Successful FDA Meeting
Veru has secured FDA feedback clearing a defined regulatory path for enobosarm, a selective androgen receptor modulator, as an...
IO Biotech to Present Promising New Melanoma Data at ESMO
IO Biotech will deliver a late-breaking oral presentation at ESMO 2025 with primary results from its randomized phase 3...
Mainz Biomed Announces New ColoAlert® Launch in Switzerland
Mainz Biomed has commercially launched ColoAlert, its non-invasive colorectal cancer screening test, in Switzerland following Swissmedic registration, a technology...
Vanderbilt Report Reveals Coeptis’s Funding Breakthrough
Coeptis Therapeutics is formalizing a dual-track operating model that pairs revenue generation with cell therapy development. In Q2 2025,...